Nuveen Asset Management, LLC Vbi Vaccines Inc Transaction History

Nuveen Asset Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.29 - $0.64 $17,072 - $37,676	-58,870 Reduced 9.29%	574,953 $172,000
Q4 2022 Feb 14, 2023	SELL	$0.38 - $22.5 $32,418 - $1.92 Million	-85,311 Reduced 11.86%	633,823 $248,000
Q3 2022 Nov 14, 2022	SELL	$0.73 - $23.4 $8,814 - $282,555	-12,075 Reduced 1.65%	719,134 $508,000
Q2 2022 Aug 15, 2022	SELL	$0.66 - $1.81 $28,201 - $77,341	-42,730 Reduced 5.52%	731,209 $591,000
Q1 2022 May 16, 2022	BUY	$1.27 - $2.47 $5,295 - $10,299	4,170 Added 0.54%	773,939 $1.2 Million
Q4 2021 Feb 14, 2022	SELL	$2.21 - $3.22 $120,935 - $176,204	-54,722 Reduced 6.64%	769,769 $1.69 Million
Q3 2021 Nov 12, 2021	BUY	$2.8 - $3.72 $15,198 - $20,192	5,428 Added 0.66%	824,491 $2.73 Million
Q2 2021 Aug 16, 2021	SELL	$2.61 - $4.17 $141,399 - $225,913	-54,176 Reduced 6.2%	819,063 $2.74 Million
Q1 2021 May 17, 2021	BUY	$2.91 - $4.32 $287,985 - $427,524	98,964 Added 12.78%	873,239 $2.72 Million
Q4 2020 Feb 16, 2021	SELL	$2.15 - $3.5 $71,145 - $115,818	-33,091 Reduced 4.1%	774,275 $2.13 Million
Q3 2020 Nov 16, 2020	SELL	$2.77 - $6.17 $16,343 - $36,403	-5,900 Reduced 0.73%	807,366 $2.31 Million
Q2 2020 Aug 14, 2020	BUY	$0.87 - $3.13 $151,476 - $544,967	174,111 Added 27.24%	813,266 $2.52 Million
Q1 2020 May 14, 2020	BUY	$0.73 - $1.91 $162,876 - $426,155	223,118 Added 53.63%	639,155 $607,000
Q4 2019 Feb 14, 2020	BUY	$0.48 - $1.38 $93,916 - $270,009	195,659 Added 88.78%	416,037 $575,000
Q2 2019 Aug 15, 2019	BUY	$0.65 - $2.12 $143,245 - $467,201	220,378 New	220,378 $257,000

688K

Ticker VBIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 258,256,992
Market Cap $5.17M
Description
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.